I think perhaps the most interesting historical lesson from GISSI 2 is that, despite there being no significant difference between SK and tPA in terms of clinical outcomes, tPA became by far the dominant thrombolytic agent in the U.S. It is a testament to the marketing power of big Pharma, in this case Genentech, to promote a drug to physicians in the face of negative trial results.
I think perhaps the most interesting historical lesson from GISSI 2 is that, despite there being no significant difference between SK and tPA in terms of clinical outcomes, tPA became by far the dominant thrombolytic agent in the U.S. It is a testament to the marketing power of big Pharma, in this case Genentech, to promote a drug to physicians in the face of negative trial results.